AN 240

Drug Profile

AN 240

Latest Information Update: 12 Nov 1998

Price : $50

At a glance

  • Originator Athena Neurosciences
  • Class Neuroprotectants; Nootropics
  • Mechanism of Action Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 12 Nov 1998 Discontinued-Unspecified Phase in Alzheimer's disease in USA (unspecified route)
  • 18 Aug 1995 Investigation in Alzheimer's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top